Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema - Wikidata - awgldk - TriplyDB

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

http://www.wikidata.org/entity/Q35575496

about

Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials Diabetic Retinopathy: Animal Models, Therapies, and Perspectives New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials Updates on the Clinical Trials in Diabetic Macular Edema Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant The clinical utility of aflibercept for diabetic macular edema Anti-VEGF Therapy and the Retina: An Update Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema The role of aflibercept in the management of diabetic macular edema Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Treatment of diabetic retinopathy: Recent advances and unresolved challenges Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory Administration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes Mellitus Update on corticosteroids for diabetic macular edema Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.Fenofibrate and Diabetic Retinopathy.High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.New Therapeutic Approaches in Diabetic Retinopathy.Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema.Demographic features and visual outcomes of patients presenting to diabetic photo-screening and treated for sight threatening retinopathy in Fiji.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.Diabetic Retinopathy: A Position Statement by the American Diabetes Association.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.

P2860

Q26750459-B12A9115-39D3-4DE8-B647-89652ED25247 Q26765466-1BE7136B-4E06-4B51-B2DB-2BF94E1038B9 Q26765468-2B327F94-BE52-4ED8-AFA3-BCB74CDFE4FE Q26767095-BC61BDAB-BEF1-4B2B-915F-E505370C8A38 Q26767100-D4D37BFE-890A-410E-A76A-3E32BAE95DBE Q26775552-CC9DE84D-87CD-4463-A4CD-E27C4557D54C Q26775853-BBAE775D-718C-4B51-BAB4-ECE5FDCA2CB3 Q26783575-668049A7-371E-4C72-9912-0A6AC308BDCD Q26784605-2C20289D-F89A-4BDD-A91E-212F99531E58 Q26786012-D0E18A9F-DF36-4D76-91C8-0917F6D6D11B Q26798348-3A034018-4449-49CD-9CB4-796DEE896AD2 Q26799492-9CF7F493-1D9A-484C-AC8F-F5C76FE3CABE Q26823985-59338505-F4F0-42AF-B075-CC44C36E2F2F Q28066675-2DE2817F-D180-4369-A35E-21DBF217254B Q28067491-4B429F0D-786B-4CDB-AE05-1929C6F00C63 Q28070894-7AB9E588-1D03-4893-A653-08355DA6B954 Q28072087-242371D9-8AF8-4547-9E86-17A72A0FC183 Q28074846-3EBCCBE6-7902-4FE6-8B09-BB333F12373D Q28075473-AF912B75-CE5D-4059-A8DB-7FF8ED1334E9 Q28075557-33C78F31-7202-46D1-A7E9-0D120C1A79E1 Q30101045-EBC53EF8-7349-451C-B37F-55939B2B33E3 Q30244247-5F43F8AE-4144-463C-9746-EFA59EE7907E Q30248492-CE87B51A-5F19-4BA2-8E1A-70B8037F5A98 Q30365660-C73B18B8-1779-40EF-AA46-6053231C3A0F Q30490738-2E7F0425-2B0F-49B3-852F-180BABC99D9C Q30491050-2415BD2D-2F6A-41CB-922F-AA4D4929A675 Q31018013-F8CA55C5-7AE2-4C77-B369-CF4B8C450F1F Q31155420-0393758F-267F-4651-B48E-925DC12A9383 Q33583037-65ADCD80-6993-4423-8538-FAA4DDD99E2E Q33706093-84DDE776-39CA-4724-BE4E-998EE16DD962 Q33706122-D1C5275A-F706-4417-AA6C-5B17267B94B8 Q33740152-4DC0AF69-6C8A-4E0E-9D31-A5B36D0BF1C6 Q33779141-E8467A7D-984E-4AC2-BDB3-AB8CF1E497C7 Q33828636-8671C167-A849-455F-8CFB-C03F1CDB8AFC Q33840787-45E9C6A6-CC0B-4F9A-BDEB-D08BED9AAF4E Q33912485-502BF78F-6651-4416-9ACC-5347C317A2DA Q34501650-C6C40868-C13C-4081-9AB1-4C791769244C Q34518374-2218AC0B-26EC-4126-81A8-51CA3D0F379A Q34551730-22CBF87E-3FA7-4B83-8AAC-0282F75CE528 Q34558187-220E74BD-3BF1-4FBE-BAA5-B721B57DB88F

P2860

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

http://www.wikidata.org/entity/Q35575496

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

@ast

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

@en

type

label

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

@ast

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

@en

prefLabel

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

@ast

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

@en

P1433

Q35575496-46B1CE25-92C8-4066-B176-46886AE2CC8C

P1476

Q35575496-01416C51-BFE6-44AB-A504-D30C0C0EF392

P2093

Q35575496-08B40204-F88B-41B0-959E-F59D6F4BB048

Q35575496-1D254EEF-1D8E-41B5-A467-8B46B523C878

Q35575496-22EAC19D-AA8D-4D68-9666-0D619BF6A1A5

Q35575496-3D040510-96C8-4B84-9661-112FE6BDB94E

Q35575496-5A3F9A47-D8A2-4B6D-8BC8-BEF5C5903123

Q35575496-5D8DD44A-A698-459A-8818-A52B2B1AE1DC

Q35575496-6E9F803C-1CD8-4690-A5CC-B10BC9E22B71

Q35575496-7406A0D9-CD4A-457C-BEAD-9E5AE8111E8B

Q35575496-744DD1C9-E667-44B8-BF04-2EEF3E2565D3

Q35575496-7B3DFD9B-3D91-4279-84E8-E9BB49F5539A

P2860

Q35575496-0340C6BC-4454-4266-855C-9A313B84EF13

Q35575496-11A9979E-3CCB-46ED-9B46-B7C761B84361

Q35575496-13AFCA29-8F6F-4DB3-B678-A611A3DF583B

Q35575496-28480480-DFA6-495C-9F9A-EDB4B405013C

Q35575496-2D2BAE6C-3708-4FC0-886E-620D866EDA6F

Q35575496-3C738A7C-0D3F-401E-ABD3-1E47E51F8732

Q35575496-3E20EA7E-F6FE-4E34-A410-AB4306013168

Q35575496-42027C22-B029-4866-A455-B223D8AB1367

Q35575496-52EC9A64-30B2-4E2D-8439-09ECFF7509D9

Q35575496-53B0060B-A615-4C6F-B508-BF53013FF275

P304

Q35575496-81257EC8-C3E0-49CB-A1BA-36E2ACFC46EC

P31

Q35575496-CE815293-B595-4459-9D6A-F7E2B4C8D133

P356

Q35575496-D57C4FA3-48F3-4427-B100-63F2CE8EBBFE

P407

Q35575496-526FF1EA-0A28-44E4-8CE8-DD34BE5999D1

P433

Q35575496-863D499A-9956-4522-B00A-D21FC2E6781E

P478

Q35575496-0843E494-0F71-42D0-9005-DD5591CC2FDA

P577

Q35575496-90C52329-2F61-4738-BAEB-5A7C5F52497C

P698

Q35575496-41248038-B03D-4F5E-80FA-DF85BE6FDE89

P921

Q35575496-F8D76BF1-AD41-46E3-AB30-4EA48199EA32

P932

Q35575496-C5CD171A-60F5-454D-B8AA-6548B2A02175

P356

P1433

The New England Journal of Medicine

P1476

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

@en

P2093

Adam R Glassman

http://www.w3.org/2001/XMLSchema#string

Allison R Ayala

http://www.w3.org/2001/XMLSchema#string

Andrew N Antoszyk

http://www.w3.org/2001/XMLSchema#string

Bambi Arnold-Bush

http://www.w3.org/2001/XMLSchema#string

Carl W Baker

http://www.w3.org/2001/XMLSchema#string

Dante J Pieramici

http://www.w3.org/2001/XMLSchema#string

David J Browning

http://www.w3.org/2001/XMLSchema#string

Diabetic Retinopathy Clinical Research Network

http://www.w3.org/2001/XMLSchema#string

Frederick L Ferris

http://www.w3.org/2001/XMLSchema#string

Jennifer K Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-vascular endothelial growth factor for diabetic macular oedema

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Ranibizumab for neovascular age-related macular degeneration

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

Resource use and costs associated with diabetic macular edema in elderly persons.

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Multiple imputation: a primer.

P304

1193-1203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1414264

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25692915

http://www.w3.org/2001/XMLSchema#string

P921

P932

4422053

http://www.w3.org/2001/XMLSchema#string